[{"id":"07f9adf4-847e-4090-bc47-0d00f756a0e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00101101","created_at":"2021-01-18T00:19:20.785Z","updated_at":"2025-02-25T15:47:08.285Z","phase":"Phase 2","brief_title":"Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma","source_id_and_acronym":"NCT00101101","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Proleukin (aldesleukin) • GM.CD40L cell vaccine • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/01/2004","start_date":" 07/01/2004","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 06/14/2021","study_completion_date":" 06/14/2021","last_update_posted":"2023-08-22"},{"id":"f07fab5c-ce2d-4eca-a500-d7501736ca16","acronym":"","url":"https://clinicaltrials.gov/study/NCT00840931","created_at":"2021-01-18T03:12:04.770Z","updated_at":"2025-02-25T14:30:42.992Z","phase":"Phase 1","brief_title":"Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT00840931","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD40LG","pipe":"","alterations":" ","tags":["CD40LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • GM.CD40L cell vaccine"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/02/2009","start_date":" 02/02/2009","primary_txt":" Primary completion: 02/17/2014","primary_completion_date":" 02/17/2014","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-12-11"},{"id":"af57e4ca-b38a-471a-ada9-a8cecac2e850","acronym":"","url":"https://clinicaltrials.gov/study/NCT01433172","created_at":"2021-01-18T05:55:23.773Z","updated_at":"2024-07-02T16:36:57.332Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer","source_id_and_acronym":"NCT01433172","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CCL21","pipe":"","alterations":" ","tags":["CCL21"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GM.CD40L cell vaccine"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 03/26/2012","start_date":" 03/26/2012","primary_txt":" Primary completion: 01/31/2016","primary_completion_date":" 01/31/2016","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2019-08-06"}]